The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Beyond chemotherapy: targeted therapies in ovarian cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3743 · Cited by 282
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,559
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids
Srinivasan, M., Sedmak, D., & Jewell, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64472-0 · Cited by 1,318
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Self-citationDetection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., Dinulescu, D. M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., MacLaughlin, D. T., & Donahoe, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603672103 · Cited by 751
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 570
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Self-citationArboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 507
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
Dantzer, F., de la Rubia, G., Ménissier-de Murcia, J., Hostomsky, Z., de Murcia, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. L., & Hartmann, L. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.020 · Cited by 475
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sørensen, P. G., Hansen, M., Sessa, C., de Swart, C. A. M., Hirsch, F. R., Lund, B., & van Houwelingen, H. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3084 · Cited by 428
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Schilder, R. J., Sill, M. W., Chen, X., Darcy, K. M., Decesare, S. L., Lewandowski, G., Lee, R. B., Arciero, C. A., Wu, H., & Godwin, A. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0462 · Cited by 258
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., Hainsworth, J. D., Garcia, A. A., Pegram, M. D., Schilder, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4221 · Cited by 252
Yang, X., Fraser, M., Moll, U. M., Basak, A., & Tsang, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0425 · Cited by 248
GORDON, A. N., FINKLER, N., EDWARDS, R. P., GARCIA, A. A., CROZIER, M., IRWIN, D. H., & BARRETT, E. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00137.x · Cited by 221
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Henriksen, R., Funa, K., Wilander, E., Bäckström, T., Ridderheim, M., & Öberg, K. (1993) · PubMed · Cited by 219
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
Bartlett, J., Langdon, S., Simpson, B., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W., Williams, A., Lessells, A., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.53 · Cited by 211
Wu, J. M., Fackler, M. J., Halushka, M. K., Molavi, D. W., Taylor, M. E., Teo, W. W., Griffin, C., Fetting, J., Davidson, N. E., De Marzo, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4082 · Cited by 202
TUTT, A. N. J., LORD, C. J., MCCABE, N., FARMER, H., TURNER, N., MARTIN, N. M., JACKSON, S. P., SMITH, G. C. M., & ASHWORTH, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 196
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian Cancers
Wiener, J. R., Windham, T. C., Estrella, V. C., Parikh, N. U., Thall, P. F., Deavers, M. T., Bast, R. C., Mills, G. B., & Gallick, G. E. (2003) · Gynecologic Oncology · doi:10.1006/gyno.2002.6851 · Cited by 175
Jayson, G. C., Parker, G. J. M., Mullamitha, S., Valle, J. W., Saunders, M., Broughton, L., Lawrance, J., Carrington, B., Roberts, C., Issa, B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.032 · Cited by 165
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
Tan, D. S. P., Lambros, M. B. K., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchiò, C., Geyer, F. C., Savage, K., Parry, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2403 · Cited by 164
Self-citationWhat is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
HAN, E., & MONK, B. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.038 · Cited by 163
Angiogenesis as a strategic target for ovarian cancer therapy
Spannuth, W. A., Sood, A. K., & Coleman, R. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1051 · Cited by 162
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
Sessa, C., De Braud, F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., & Jaffe, R. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64467-7 · Cited by 161
De Placido, S., Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.088 · Cited by 161
Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K. F., Sevelda, P., & Zeillinger, R. (1997) · PubMed · Cited by 156
Puiffe, M., Page, C. L., Filali-Mouhim, A., Zietarska, M., Ouellet, V., Tonin, P. N., Chevrette, M., Provencher, D. M., & Mes‐Masson, A. (2007) · Neoplasia · doi:10.1593/neo.07472 · Cited by 153
Futreal, P. A., Kasprzyk, A., Birney, E., Mullikin, J. C., Wooster, R., & Stratton, M. R. (2001) · Nature · doi:10.1038/35057046 · Cited by 152
Nimeiri, H. S., Oza, A. M., Morgan, R. J., Friberg, G. R., Kasza, K., Faoro, L. N., Salgia, R., Stadler, W. M., Vokes, E. E., & Fleming, G. F. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.009 · Cited by 151
Late Congestive Heart Failure After Hematopoietic Cell Transplantation
Armenian, S. H., Sun, C., Francisco, L., Steinberger, J., Kurian, S., Wong, F. L., Sharp, J., Sposto, R., Forman, S. J., & Bhatia, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7428 · Cited by 150
Workman, P. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455279 · Cited by 150
Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J. J., & Fidler, I. J. (2000) · International Journal of Oncology · doi:10.3892/ijo.16.3.445 · Cited by 148
Posadas, E. M., Liel, M. S., Kwitkowski, V. E., Minasian, L. M., Godwin, A. K., Hussain, M. M., Espina, V. A., Wood, B. J., Steinberg, S. M., & Kohn, E. C. (2007) · Cancer · doi:10.1002/cncr.22545 · Cited by 143
Ebel, W., Routhier, E., Foley, B., Jacob, S. M., McDonough, J., Patel, R. K., Turchin, H. A., Chao, Q., Kline, J. B., Old, L. J., et al. (2007) · PubMed · Cited by 137
Seiden, M. V., Burris, H. A., Matulonis, U. A., Hall, J. B., Armstrong, D. K., Speyer, J. L., Weber, J., & Muggia, F. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.019 · Cited by 134
Secord, A. A., Blessing, J. A., Armstrong, D. K., Rodgers, W. H., Miner, Z., Barnes, M. N., Lewandowski, G. S., & Mannel, R. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.029 · Cited by 132
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
Sandercock, J., Parmar, M., Torri, V., & Qian, W. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600567 · Cited by 128
Hu, L., Hofmann, J., Holash, J. A., Yancopoulos, G. D., Sood, A. K., & Jaffe, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0910 · Cited by 127
Matei, D. E., Chang, D. D., & Jeng, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0754-03 · Cited by 123
Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer
Burger, R. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1509 · Cited by 113
Angiogenesis in normal and neoplastic ovaries
Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y., & Geller, M. A. (2005) · Angiogenesis · doi:10.1007/s10456-005-9001-1 · Cited by 112
Schilder, R. J., Sill, M. W., Lee, R. B., Shaw, T. J., Senterman, M. K., Klein–Szanto, A. J., Miner, Z., & Vanderhyden, B. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3420 · Cited by 110
Campos, S. M., Hamid, O., Seiden, M. V., Oza, A. M., Plante, M., Potkul, R. K., Lenehan, P. F., Kaldjian, E. P., Varterasian, M. L., Jordan, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.091 · Cited by 106
Micha, J. P., Goldstein, B. H., Rettenmaier, M. A., Genesen, M. C., Graham, C. L., Bader, K., Lopez, K., Nickle, M. A., & Brown, J. V. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00886.x · Cited by 106
Tew, W. P., Colombo, N., Ray-Coquard, I. L., Oza, A. M., del Campo, J., Scambia, G., & Spriggs, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5508 · Cited by 106
PTEN and p53: Who will get the upper hand?
Trotman, L. C., & Pandolfi, P. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00022-9 · Cited by 105
Workman, P. (2003) · PubMed · Cited by 105
Coleman, R. L., Broaddus, R. R., Bodurka, D. C., Wolf, J. K., Burke, T. W., Kavanagh, J. J., Levenback, C. F., & Gershenson, D. M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.041 · Cited by 104
for the ET-743-INT-11 study group, Krasner, C. N., McMeekin, D. S., Chan, S. Y. T., Braly, P. S., Renshaw, F. G., Kaye, S. B., Provencher, D. M., Campos, S. M., & Gore, M. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604088 · Cited by 103
Self-citationBookman, M. A., Greer, B. E., & Ozols, R. F. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13602.x · Cited by 103
Gibbs, D. D., Theti, D. S., Wood, N., Green, M., Raynaud, F. I., Valenti, M. R., Forster, M. D., Mitchell, F., Bavetsias, V., Henderson, E. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2034 · Cited by 101
Schilder, R. J., Pathak, H. B., Lokshin, A. E., Holloway, R. W., Alvarez, R. D., Aghajanian, C. A., Min, H., Devarajan, K., Ross, E. A., Drescher, C. W., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.003 · Cited by 99
Studies with ZD1839 in preclinical models
Sirotnak, F. M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50028 · Cited by 93
Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., & Zask, A. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5334 · Cited by 92
WAGNER, U., duBois, A., Pfisterer, J., Huober, J., Loibl, S., Lück, H., Sehouli, J., Gropp, M., Stähle, A., & Schmalfeldt, B. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.053 · Cited by 89
Konner, J. A., Schilder, R. J., Derosa, F., Gerst, S. R., Tew, W. P., Sabbatini, P. J., Hensley, M. L., Spriggs, D. R., & Aghajanian, C. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.018 · Cited by 88
du Bois, A., Neijt, J. P., & Thigpen, J. T. (1999) · Annals of Oncology · doi:10.1023/a:1008355317514 · Cited by 85
Nagy, J. A., Meyers, M., Masse, E., Herzberg, K. T., & Dvorak, H. F. (1995) · PubMed · Cited by 80
Martin, L. P., & Schilder, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1088 · Cited by 79
New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents
Dinh, P., Harnett, P. R., Piccart, M. J., & Awada, A. H. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.012 · Cited by 78
Matei, D. E., Emerson, R. E., Schilder, J. M., Menning, N., Baldridge, L. A., Johnson, C. S., Breen, T., McClean, J., Stephens, D., Whalen, C., et al. (2008) · Cancer · doi:10.1002/cncr.23605 · Cited by 74
Translating basic cancer research into new cancer therapeutics
Workman, P., & Kaye, S. B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02319-5 · Cited by 74
Self-citationmTOR and cancer: reason for dancing at the crossroads?
THOMAS, G. V. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.003 · Cited by 72
Alberts, D. S., Liu, P. Y., Wilczynski, S. P., JANG, A., MOON, J., Ward, J. H., BECK, J. T., Clouser, M. C., & Markman, M. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00882.x · Cited by 70
Garofalo, A., Naumova, E., Manenti, L., Ghilardi, C., Ghisleni, G., Caniatti, M., Colombo, T., Cherrington, J. M., Scanziani, E., Nicoletti, M. I., et al. (2003) · PubMed · Cited by 63
Kavanagh, J. J., Gershenson, D. M., Choi, H. J., LEWIS, L., PATEL, K., BROWN, G. L., García, A. A., & Spriggs, D. R. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00114.x · Cited by 61
Naumova, E., Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E., Scanziani, E., Eccles, S. A., Bani, M. R., & Giavazzi, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1615 · Cited by 61
A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer
Posadas, E. M., Kwitkowski, V. E., Kotz, H. L., Espina, V. A., Minasian, L. M., Tchabo, N. E., Premkumar, A., Hussain, M. M., Chang, R., Steinberg, S. M., et al. (2007) · Cancer · doi:10.1002/cncr.22757 · Cited by 60
Surgical management of ovarian cancer
Mutch, D. G. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31589 · Cited by 60
Yoshiji, H., Kuriyama, S., Hicklin, D. J., Huber, J., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., & Fukui, H. (2001) · Hepatology · doi:10.1053/jhep.2001.23312 · Cited by 56
Hu, L., Hofmann, J., & Jaffe, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0206 · Cited by 55
Oza, A. M., Elit, L., Provencher, D. M., Biagi, J. J., Panasci, L., Sederias, J., Dancey, J. E., Tsao, M., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5516 · Cited by 53
on behalf of the Scottish Gynaecological Cancer Trials Group, Vasey, P. A., Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Pujade-Lauraine, É., Paul, J., Carty, K., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604371 · Cited by 49
Self-citationTelomerase as a Target for Cancer Immunotherapy
Nguyen, B., Elmore, L. W., & Holt, S. E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.255 · Cited by 48
町田, 静., Saga, Y., Takei, Y., Mizuno, I., Takayama, T., Kohno, T., Konno, R., Ohwada, M., & Suzuki, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20751 · Cited by 42
Slomovitz, B. M., Lu, K. H., Johnston, T., Munsell, M. A., Ramondetta, L. M., Broaddus, R. R., Coleman, R. L., Walker, C., Gershenson, D. M., Burke, T. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5502 · Cited by 39
Armstrong, D. K., Bicher, A., Coleman, R. L., Gibbon, D. G., Glenn, D., Old, L. J., Senzer, N. N., Schneeweiß, A., Verheijen, R. H. M., White, A. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5500 · Cited by 38
Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells
Forster, M. D., Ormerod, M. G., Agarwal, R., Kaye, S. B., & Jackman, A. L. (2007) · Cytometry Part A · doi:10.1002/cyto.a.20456 · Cited by 32
Self-citationForster, M. D., Kaye, S. B., Oza, A. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1653 · Cited by 31
Self-citation
Cited by
Zheng, H., Zhang, Y., Liu, L., Wan, W., Guo, P., Nyström, A. M., & Zou, X. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11720 · Cited by 1,383
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationIntrinsic therapeutic applications of noble metal nanoparticles: past, present and future
Arvizo, R. R., Bhattacharyya, S., Kudgus, R. A., Giri, K., Bhattacharya, R., & Mukherjee, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15355f · Cited by 866
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
Metadata
- Authors
- Yap, T. A., Carden, C. P., & Kaye, S. B.
- Venue
- Nature Reviews Cancer
- Published
- 2009-03
- Volume
- 9
- Issue
- 3
- Pages
- 167-181
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088561077
- Cited by
- 495
- References
- 133
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.